Progress against lung cancer, Denmark, 2008–2022
DOI:
https://doi.org/10.2340/1651-226X.2024.26180Keywords:
Stage, Incidence, Survival, MortalityAbstract
Background and purpose: There has been marked progress against lung cancer in Denmark. To gain further insight into the different aspects of the improvement, we examined the stage-specific incidence rates, stage-specific survival and mortality rates.
Materials and methods: We used information from the Danish Lung Cancer Registry on date of diagnosis and clinical stage to calculate age-standardised incidence rates and patient survival by sex, period and stage. Information about age-standardised lung cancer-specific mortality rates by sex and period was extracted from The Danish Health Data Authority.
Results: Firstly, the decrease in incidence rates was due to a reduction in the rates of advanced stages. Secondly, there was a gradual increase in survival across all stages, and thirdly, the mortality rates gradually decreased over time.
Interpretation: The improvements in survival and mortality from lung cancer were due to decreasing incidence rates of advanced cancer and improvement in survival at all stages of the disease.
Downloads
References
Measuring progress against cancer, Fremskridt mod kræft [Internet]. [cited 26-10-2023]. Available from: https://www.rkkp.dk/siteassets/nyheder/seks-krafttyper-dashboard-230312-1.pdf
Jakobsen E, Rasmussen TR. The Danish lung cancer registry. Clin Epidemiol. 2016;8:537–41.
https://doi.org/10.2147/CLEP.S99458 DOI: https://doi.org/10.2147/CLEP.S99458
Yim C. Imputing missing data using SAS, paper 3295-2015 [Internet]. [cited 11-10-2023]. Available from: https://support.sas.com/resources/papers/proceedings15/3295-2015.pdf
Brenner H, Söderman B, Hakulinen T. Use of period analysis for more up-to-date estimates of long-term survival rates: empirical evaluation among 370 000 cancer patients in Finland. Int J Epidemiol. 2002;31(2):456–62. DOI: https://doi.org/10.1093/intjepid/31.2.456
https://doi.org/10.1093/ije/31.2.456 DOI: https://doi.org/10.1093/ije/31.2.456
Foreman AJ, Lai GP, Miller DP. Surviving left truncation using PROC PHREG [Internet]. [cited 11-10-2023]. Available from: https://www.lexjansen.com/wuss/2008/anl/anl03.pdf
The Danish Health Data Authority, [cited 10-07-2023]. Available from: https://www.esundhed.dk/Emner/Hvad-doer-vi-af/Doedsaarsager
Jakobsen E, Olsen KE, Bliddal M, et al. Forecasting lung cancer incidence, mortality, and prevalence to year 2030. BMC Cancer. 2021;21(1):985.
https://doi.org/10.1186/s12885-021-08696-6 DOI: https://doi.org/10.1186/s12885-021-08696-6
Borg M, Hilberg O, Andersen MB, et al. Increased use of computed tomography in Denmark: stage shift toward early stage lung cancer through incidental findings. Acta Oncol. 2022 Oct;61(10):1256–1262.
https://doi.org/10.1080/0284186X.2022.2135134 DOI: https://doi.org/10.1080/0284186X.2022.2135134
Hyldgaard C, Trolle C, Harders SMW, et al. Increased use of diagnostic CT imaging increases the detection of stage IA lung cancer: pathways and patient characteristics. BMC Cancer. 2022;22(1):464.
https://doi.org/10.1186/s12885-022-09585-2 DOI: https://doi.org/10.1186/s12885-022-09585-2
National Lung Screening Trial Research Team. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med. 2011;365:395–40.
https://doi.org/10.1056/NEJMoa1102873 DOI: https://doi.org/10.1056/NEJMoa1102873
Published
How to Cite
License
Copyright (c) 2023 Marianne Steding-Jessen, Henriette Engberg, Erik Jakobsen, Torben Riis Rasmussen, Henrik Møller
This work is licensed under a Creative Commons Attribution 4.0 International License.
